KR20240124925A - 아미노피라졸 화합물의 용도 - Google Patents
아미노피라졸 화합물의 용도 Download PDFInfo
- Publication number
- KR20240124925A KR20240124925A KR1020247020622A KR20247020622A KR20240124925A KR 20240124925 A KR20240124925 A KR 20240124925A KR 1020247020622 A KR1020247020622 A KR 1020247020622A KR 20247020622 A KR20247020622 A KR 20247020622A KR 20240124925 A KR20240124925 A KR 20240124925A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- compound according
- dogs
- jak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21217736 | 2021-12-24 | ||
| EP21217736.4 | 2021-12-24 | ||
| PCT/EP2022/087698 WO2023118555A1 (en) | 2021-12-24 | 2022-12-23 | Use of aminopyrazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240124925A true KR20240124925A (ko) | 2024-08-19 |
Family
ID=79025165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247020622A Pending KR20240124925A (ko) | 2021-12-24 | 2022-12-23 | 아미노피라졸 화합물의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049775A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4452970A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024545293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240124925A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118541364A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022418280A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242449A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007863A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023118555A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021335500A1 (en) | 2020-09-04 | 2023-05-04 | Elanco Us Inc. | Palatable formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3951899A (en) | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| RS53382B (sr) | 2008-08-20 | 2014-10-31 | Zoetis Llc | Jedinjenja pirol [2,3-d]pirimidina |
| AU2012312303B2 (en) | 2011-09-22 | 2016-09-15 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
| WO2014146246A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
| AU2017376398B2 (en) | 2016-12-14 | 2021-07-15 | Intervet International B.V. | Aminopyrazoles as selective janus kinase inhibitors |
| KR20220119024A (ko) * | 2019-12-20 | 2022-08-26 | 인터벳 인터내셔널 비.브이. | 피라졸 제약 조성물 |
-
2022
- 2022-12-23 WO PCT/EP2022/087698 patent/WO2023118555A1/en not_active Ceased
- 2022-12-23 US US18/721,916 patent/US20250049775A1/en active Pending
- 2022-12-23 JP JP2024537401A patent/JP2024545293A/ja active Pending
- 2022-12-23 CA CA3242449A patent/CA3242449A1/en active Pending
- 2022-12-23 AU AU2022418280A patent/AU2022418280A1/en active Pending
- 2022-12-23 CN CN202280084861.5A patent/CN118541364A/zh active Pending
- 2022-12-23 KR KR1020247020622A patent/KR20240124925A/ko active Pending
- 2022-12-23 MX MX2024007863A patent/MX2024007863A/es unknown
- 2022-12-23 EP EP22844123.4A patent/EP4452970A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3242449A1 (en) | 2023-06-29 |
| JP2024545293A (ja) | 2024-12-05 |
| US20250049775A1 (en) | 2025-02-13 |
| CN118541364A (zh) | 2024-08-23 |
| AU2022418280A1 (en) | 2024-06-13 |
| MX2024007863A (es) | 2024-08-30 |
| WO2023118555A1 (en) | 2023-06-29 |
| EP4452970A1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025092508A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| KR20050113163A (ko) | 모다피닐의 제약 제제 | |
| ES2750662T3 (es) | Orvepitant para el tratamiento del prurito crónico | |
| JP6668045B2 (ja) | ドラベ症候群を処置するための選択的5−ht受容体アゴニストおよびアンタゴニスト | |
| AU2024264660A1 (en) | Methods of treating behavior alterations | |
| CN101678018A (zh) | 用于治疗精神分裂症的(硫代)-氨甲酰基-环己烷衍生物和方法 | |
| WO2021016369A1 (en) | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder | |
| US20220117925A1 (en) | Methods of treating or alleviating mental disorders and associated symptoms | |
| US20250049775A1 (en) | Use of aminopyrazole compounds | |
| EP2029139B1 (en) | Use of a p38 kinase inhibitor for treating psychiatric disorders | |
| JP2022528520A (ja) | プレガバリン製剤およびその使用 | |
| US20190247405A1 (en) | Treatment of sma | |
| TWI864376B (zh) | 焦慮症處置用組成物及處置方法 | |
| Cole et al. | Treatment of equine nervous system disorders | |
| Gruen et al. | Drugs affecting animal behavior | |
| EP3727587A1 (en) | Compositions and methods for williams syndrome (ws) therapy | |
| WO2022107146A1 (en) | Use of pridopidine and analogs for treating rett syndrome | |
| CN108078984A (zh) | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 | |
| RU2799049C2 (ru) | Способы лечения изменений поведения | |
| HK40119716A (en) | Compositions and methods for treating and preventing diseases using tirilazad salts | |
| HK40122445A (en) | Methods of treating behavior alterations | |
| CN111432813A (zh) | 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物 | |
| EP2271342B1 (en) | Use of nicotinamide for treating summer itch in horses | |
| HK40115079A (en) | Methods, dosage regimens, and compositions for treating hidradenitis | |
| WO2020174238A1 (en) | Prochlorperazine for the treatment of pitt-hopkins syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |